Literature DB >> 23949559

Risk of breast cancer by individual insulin use: an international multicenter study.

Lamiae Grimaldi-Bensouda1, David Cameron, Michel Marty, Anthony H Barnett, Frédérique Penault-Llorca, Michael Pollak, Bernard Charbonnel, Matthew Riddle, Laurent Mignot, Jean-François Boivin, Artak Khachatryan, Michel Rossignol, Jacques Bénichou, Annick Alpérovitch, Lucien Abenhaim.   

Abstract

OBJECTIVE Several studies have been published in 2009 suggesting a possible association between insulin glargine and increased risk of malignancies, including breast cancer. The objective of this study was to assess the relation between the individual insulins (glargine, aspart, lispro, and human insulin) and development of breast cancer. RESEARCH DESIGN AND METHODS Seven hundred seventy-five incident cases of primary invasive or in situ carcinoma breast cancer occurring in women with diabetes from 92 centers in the U.K., Canada, and France were matched to a mean of 3.9 diabetic community control subjects (n = 3,050; recruited from 580 general practices) by country, age, recruitment date, and diabetes type and management. The main risk model was a multivariate conditional logistic regression model with case/control status as the dependent variable and individual insulin use, 8 years preceding the index date, as the independent variable, controlling for past use of any insulin, oral antidiabetes drugs, reproductive factors, lifestyle, education, hormone replacement therapy and history of contraceptive use, BMI, comorbidities, diabetes duration, and annual number of physician visits. Glargine was also compared with every other insulin by computing all ratios using the variance-covariance matrix of logistic model parameters. RESULTS Adjusted odds ratios of breast cancer for each type of insulin versus no use of that insulin were 1.04 (95% CI 0.76-1.44) for glargine, 1.23 (0.79-1.92) for lispro, 0.95 (0.64-1.40) for aspart, and 0.81 (0.55-1.20) for human insulin. Two-by-two comparisons found no difference between glargine and the different types of insulins. Insulin dosage or duration of use and tumor stage did not change the results. CONCLUSIONS This international study found no difference in the risk of developing breast cancer in patients with diabetes among the different types of insulin with short- to mid-term duration of use. Longer-term studies would be of interest.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23949559     DOI: 10.2337/dc13-0695

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  6 in total

1.  Muscular Adverse Drug Reactions Associated with Proton Pump Inhibitors: A Disproportionality Analysis Using the Italian National Network of Pharmacovigilance Database.

Authors:  Alice Capogrosso Sansone; Irma Convertino; Maria Teresa Galiulo; Stefano Salvadori; Stefania Pieroni; Tamara Knezevic; Stefania Mantarro; Alessandra Marino; Manfred Hauben; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2017-10       Impact factor: 5.606

Review 2.  Insulin and IGFs in obesity-related breast cancer.

Authors:  Valentina Belardi; Emily J Gallagher; Ruslan Novosyadlyy; Derek LeRoith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2013-10-24       Impact factor: 2.673

3.  Diabetes and Breast Cancer Subtypes.

Authors:  Heleen K Bronsveld; Vibeke Jensen; Pernille Vahl; Marie L De Bruin; Sten Cornelissen; Joyce Sanders; Anssi Auvinen; Jari Haukka; Morten Andersen; Peter Vestergaard; Marjanka K Schmidt
Journal:  PLoS One       Date:  2017-01-11       Impact factor: 3.240

4.  Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence.

Authors:  Heleen K Bronsveld; Bas ter Braak; Øystein Karlstad; Peter Vestergaard; Jakob Starup-Linde; Marloes T Bazelier; Marie L De Bruin; Anthonius de Boer; Christine L E Siezen; Bob van de Water; Jan Willem van der Laan; Marjanka K Schmidt
Journal:  Breast Cancer Res       Date:  2015-08-05       Impact factor: 6.466

5.  Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml.

Authors:  A Steinstraesser; R Schmidt; K Bergmann; R Dahmen; R H A Becker
Journal:  Diabetes Obes Metab       Date:  2014-03-24       Impact factor: 6.577

6.  Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats.

Authors:  Yusaku Mori; Eunhyoung Ko; Rudolf Furrer; Linda C Qu; Stuart C Wiber; I George Fantus; Mario Thevis; Alan Medline; Adria Giacca
Journal:  Endocr Connect       Date:  2018-04-24       Impact factor: 3.335

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.